The OTEZLA® international website

This site is intended for healthcare professionals outside the U.S.

Country Sites U.S. Residents

Plaque  Psoriasis

Plaque  Psoriasis

Clinical Efficacy

Clinical Efficacy

Safety

Safety

Dosing

Dosing

Mechanism of Action

Mechanism of Action

Testimonials

Testimonials

About Psoriasis

About Psoriasis

Resources

Resources

Psoriatic  Arthritis

Psoriatic  Arthritis

Clinical Efficacy

Clinical Efficacy

Safety

Safety

Dosing

Dosing

Mechanism of Action

Mechanism of Action

About Psoriatic Arthritis

About Psoriatic Arthritis

Treatment Recommendations

Treatment Recommendations

Resources

Resources

PSORIATIC ARTHRITIS IS A COMPLEX DISEASE INVOLVING 6 KEY DOMAINS1,2

The manifestations of PsA are driven by disregulation of multiple pro-inflammatory cytokines3-17

Human silhouette illustrating the 6 key domains of psoriatic arthritis: skin psoriasis, axial disease, nail psoriasis, enthesitis, dactylitis, and peripheral arthritis

When treating psoriatic arthritis, consider the value of a medication that impacts the 6 key domains19

Visual representation based on clinical and preclinical evidence.

DMARD, disease-modifying antirheumatic drug; IFN, interferon; IL, interleukin; TNF, tumor necrosis factor; Th, T helper.

References:

  1. Gottlieb A, Korman NJ, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol. 2008;58(5)851-864.
  2. Gossec L, Smolen JS, Ramiro S, et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis. 2016;75:499-510.
  3. Lee E, Trepicchio WL, Oestreicher JL, et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med. 2004;199(1):125-130.
  4. Lowes MA, Kikuchi T, Fuentes-Duculan J, et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol. 2008;128(5):1207-1211.
  5. Yao Y, Richman L, Morehouse C, et al. Type I interferon: potential therapeutic target for psoriasis? PLoS One. 2008;3(7):e2737.
  6. Villanova F, Di Meglio P, Nestle FO. Biomarkers in psoriasis and psoriatic arthritis. Ann Rheum Dis. 2013;72 (suppl 2): ii104-ii110.
  7. Van Kuijk AW, Tak PP. Synovitis in psoriatic arthritis: immunohistochemistry, comparisons with rheumatoid arthritis, and effects of therapy. Curr Rheumatol Rep. 2011;13(4):353-359.
  8. Menon B, Gullick NJ, Walter GJ, et al. Interleukin-17+CD8+ T cells are enriched in the joints of patients with psoriatic arthritis and correlate with disease activity and joint damage progression. Arthritis Rheumatol. 2014;66(5):1272-1281.
  9. Celis R, Planell N, Fernández-Sueiro JL, et al. Synovial cytokine expression in psoriatic arthritis and associations with lymphoid neogenesis and clinical features. Arthritis Res Ther. 2012;14(2):R93.
  10. Siegel EL, Orbai AM, Ritchlin CT. Targeting extra-articular manifestations in PsA: a closer look at enthesitis and dactylitis. Curr Opin Rheumatol. 2015;27(2):111-117.
  11. Taylan A, Sari I, Kozaci DL, et al. Evaluation of the T helper 17 axis in ankylosing spondylitis. Rheumatol Int. 2012;32(8):2511-2515.
  12. Limon-Camacho L, Vargas-Rojas MI, Vazquez-Mellado J, et al. In vivo peripheral blood proinflammatory t cells in patients with ankylosing spondylitis. J Rheumatol. 2012;39(4):830-835.
  13. Kyriakou A, Patsatsi A, Vyzantiadis TA, Sotiriadis D. Serum levels of TNF-α, IL-12/23 p40, and IL-17 in psoriatic patients with and without nail psoriasis: a cross-sectional study. Scientific World Journal. 2014;2014:508178.
  14. Ebihara S, Date F, Dong Y, Ono M. Interleukin-17 is a critical target for the treatment of ankylosing enthesitis and psoriasis-like dermatitis in mice. Autoimmunity. 2015;48(4):259-266.
  15. Yamamoto M, Nakajima K, Takaishi M, et al. Psoriatic inflammation facilitates the onset of arthritis in a mouse model. J Invest Dermatol. 2015;135(2):445-453.
  16. Sherlock JP, Joyce-Shaikh B, Turner SP, et al. IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4-CD8-entheseal resident T cells. Nat Med. 2012;18(7):1069-1076.
  17. Ruutu M, Thomas G, Steck R, et al. β-glucan triggers spondylarthritis and Crohn's disease-like ileitis in SKG mice. Arthritis Rheum. 2012;64(7):2211-2222.
  18. Coates LC, Kavanaugh A, Mease PJ, et al. Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol. 2016;68(5):1060-1071.
  19. Marchesoni A. Oligoarticular Psoriatic Arthritis: Addressing Clinical Challenges in an Intriguing Phenotype. Rheumatol Ther. 2018;5(2):311–316.
You are leaving the OTEZLA® (apremilast) website
Do you wish to leave this site?
OTEZLA International Websites
OTEZLA is approved in 54 countries*

  • United States

  • Canada

  • Australia

  • Israel

  • Switzerland

  • New Zealand

  • Austria

  • Belgium

  • Bulgaria

  • Croatia

  • Republic of Cyprus

  • Czech Republic

  • Denmark

  • Estonia

  • Finland

  • France

  • Germany

  • Greece

  • Hungary

  • Ireland

  • Italy

  • Latvia

  • Lithuania

  • Luxembourg

  • Malta

  • Netherlands

  • Poland

  • Portugal

  • Romania

  • Slovakia

  • Slovenia

  • Singapore

  • Spain

  • Sweden

  • United Kingdom

  • Norway

  • Iceland

  • Liechtenstein

  • Russia

  • Japan

  • Hong Kong

  • Kuwait

  • Taiwan

  • UAE

  • South Korea

  • Thailand

  • Lebanon

  • Qatar

  • Argentina

  • Mexico

  • Brazil

  • Malaysia

  • Oman

  • Saudi Arabia

On November 21, 2019, Amgen acquired from Celgene Corporation the worldwide rights to Otezla® (apremilast).

Effective November 21, 2019, refer to the Amgen's Terms of Use relating to the access of Amgen websites, applications and digital services and Privacy Statement concerning the collection and use of your personal information.

For information collected by Celgene prior to November 21, 2019, refer to Celgene's Terms of Use and Privacy Policy.